Popular stocks
Vale S.A.
NVIDIA
AppLovin
MicroAlgo
GameStop
Boeing
Alibaba
TAL Education
Shopify
Dell Technologies
Shares of other companies:
Microsoft: A Critical Point in Valuation Momentum
May 23, 2025
May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions
In today’s data-driven business landscape, the ability to accurately measure and optimize marketing efforts has become a critical competitive advantage. As marketing evolves,…
May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?
Trading is a very popular endeavor these days, and for good reason, as it is widely accessible and allows individuals to generate additional…
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
What defines a successful crypto expert? The amount of money earned, the number of luxury cars and international real estate? The presence of…
March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer
You can use electronic exchange services if you need to exchange the digital asset USDC ERC20 to Bank Transfer. It is not recommended…
February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio
Most investors who want to expand their investment options put their money in different asset types and industries across many areas in the…
MRNA Stock News of Moderna, Inc. Stocktwits
Updated: May 24, 2025 (09:13)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 40 days where Moderna Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Moderna, Inc..
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Moderna stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Stocktwits of Moderna, Inc. (MRNA)
May 22, 2025 (16:35) / "Zacks Commentary" (by Ekta Bagri)
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More
BMRN and NVAX are in the spotlight this week following announcement agreement and regulatory update.
In Article Trend: Somewhat-Bullish
May 22, 2025 (14:48) / "Zacks Commentary" (by Zacks Equity Research)
MRNA Stock Down on Withdrawal of FDA Filing for COVID-Flu Combo Shot
Moderna's voluntary withdrawal of the filing stems from the FDA's request for vaccine efficacy data from a phase III study on the experimental flu shot.
In Article Trend: Neutral
May 21, 2025 (12:37) / "Zacks Commentary" (by Sundeep Ganoria)
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
In Article Trend: Neutral
May 21, 2025 (10:42) / "Benzinga" (by Tanya Rawat)
FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr. - Moderna ( NASDAQ:MRNA ) , BioNTech ( NASDAQ:BNTX )
The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter clinical trial requirements for healthy adults.
In Article Trend: Somewhat-Bullish
May 20, 2025 (20:34) / "CNBC"
Healthy Returns: Novavax scores narrower Covid vaccine approval after delay
The FDA approved Novavax's Covid-19 vaccine but with unusual restrictions.
In Article Trend: Somewhat-Bullish
May 20, 2025 (19:10) / "Benzinga" (by Vaishali Prayag)
What's Going On With Vaccine Stocks Today? - BioNTech ( NASDAQ:BNTX )
Vaccine stocks are rising after the FDA announced it will consider updating COVID-19 vaccines to target the rapidly spreading LP.8.1. The FDA will require new clinical trials for annual boosters in healthy people under 65, limiting this fall's shots.
In Article Trend: Somewhat-Bullish
May 20, 2025 (14:00) / "Benzinga" (by Benzinga Insights)
How Is The Market Feeling About Moderna? - Moderna ( NASDAQ:MRNA )
Moderna's MRNA short percent of float has risen 6.97% since its last report. The company recently reported that it has 60.22 million shares sold short, which is 21.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 9.55 days to cover their ...
In Article Trend: Somewhat-Bullish
May 19, 2025 (13:42) / "Zacks Commentary" (by Zacks Equity Research)
NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.
In Article Trend: Neutral
May 19, 2025 (08:57) / "Motley Fool" (by Jon Quast)
Deckers Stock Is Among the Worst Performers in the S&P 500 in 2025. Should Investors Buy the Dip?
Shares of shoe company Deckers Outdoor ( NYSE: DECK ) are down about 37% in 2025, as of this writing, giving it the third worst performance for a constituent of the S&P 500. It only trails Moderna and UnitedHealth Group so far this year.The underperformance extends beyond this year.
In Article Trend: Somewhat-Bullish
May 16, 2025 (18:03) / "Benzinga" (by Benzinga Insights)
Moderna's Options Frenzy: What You Need to Know - Moderna ( NASDAQ:MRNA )
Financial giants have made a conspicuous bearish move on Moderna. Our analysis of options history for Moderna MRNA revealed 16 unusual trades. Delving into the details, we found 18% of traders were bullish, while 62% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
May 16, 2025 (09:30) / "Motley Fool" (by Prosper Junior Bakiny)
1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid
Equity markets are full of bargains -- stocks that have performed terribly in recent months, whether due to trade-related marketwide issues or company-specific troubles, but could bounce back once things improve. There are also companies that are not performing well and are unlikely to rebound ...
In Article Trend: Neutral
May 16, 2025 (08:15) / "Motley Fool" (by Daniel Foelber)
UnitedHealth Is One of the Worst S&P 500 Stocks In 2025. Here's Why It's Having an Even Bigger Impact on the Dow Jones.
Healthcare insurance giant UnitedHealth Group ( NYSE: UNH ) has seen its stock go from a stable stalwart to a falling knife, seemingly overnight. The stock's price crashed 22.4% on April 17 in response to its first-quarter earnings results and full-year guidance cut.
In Article Trend: Neutral
May 14, 2025 (11:30) / "GlobeNewswire" (by Arbutus Biopharma Corporation)
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B ( cHBV ) to date, including 2 patients who received no interferon ...
In Article Trend: Neutral
May 12, 2025 (10:50) / "Benzinga" (by Globe Newswire)
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - CytomX Therapeutics ( NASDAQ:CTMX )
SOUTH SAN FRANCISCO, Calif., May 12, 2025 ( GLOBE NEWSWIRE ) -- CytomX Therapeutics, Inc. CTMX, a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923,076 shares of its common stock at an offering price of ...
In Article Trend: Neutral
May 12, 2025 (10:15) / "Benzinga" (by Globe Newswire)
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - CytomX Therapeutics ( NASDAQ:CTMX )
- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate ( CX-2051 ) in Patients with Advanced Colorectal Cancer ( CRC ) - - Initiated CX-2051 Phase 1 dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses.
In Article Trend: Neutral
May 12, 2025 (10:15) / "GlobeNewswire" (by CytomX Therapeutics Inc.)
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate ( CX-2051 ) Candidate in Patients with Advanced Colorectal Cancer ( CRC )
- 28% confirmed response rate ( 5/18 ) per RECIST v1.1 in unselected patients across doses prioritized for expansion ( 7.2, 8.6 and ...
In Article Trend: Neutral
May 12, 2025 (10:15) / "GlobeNewswire" (by CytomX Therapeutics Inc.)
CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
- Announced Positive Interim Data From Ongoing Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate ( CX-2051 ) in Patients with Advanced Colorectal Cancer ( CRC ...
In Article Trend: Neutral
May 11, 2025 (01:40) / "Benzinga" (by PRNewswire)
Ellis Island Honors Society Presents the 2025 Ellis Island Medals of Honor
Leaders in business, education, entertainment, public service, philanthropy, media, healthcare, sports, and the defense of the United Stateshonored with the prestigious Ellis Island Medals of HonorDuring Gala on Ellis Island **** Her Majesty Queen Silvia of Sweden,Receives Global Humanitarian ...
In Article Trend: Bullish
May 9, 2025 (17:26) / "Benzinga" (by James Gornick)
New FDA Leadership Could Raise The Bar For Drug Approvals
New FDA Leadership Team: The FDA's top leadership has shifted under Commissioner Dr. Marty Makary, with Dr. Vinayak "Vinay" Prasad now heading the Center for Biologics Evaluation and Research ( CBER ) and Dr. Sanjula Jain-Nagpal serving as Associate Director of Policy & Research Strategy in the ...
In Article Trend: Somewhat-Bullish
May 7, 2025 (13:56) / "Benzinga" (by Vandana Singh)
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Virtus LifeSci Biotech Clinical Trials ETF ( ARCA:BBC ) , Capricor Therapeutics ( NASDAQ:CAPR )
Virtus BBC ETF fell 9.74% to $17.15; SPDR XBI ETF dropped 6.63% to $77.17 on Tuesday. William Blair says Moderna faces increased scrutiny with mRNA vaccines under new CBER leadership. Get prepared for the Fed's next move-live with Matt Maley on Wednesday, May 7 at 6 PM ET. Reserve your free spot ...
In Article Trend: Neutral
May 7, 2025 (13:26) / "Zacks Commentary" (by Zacks Equity Research)
Stock Market News for May 7, 2025
Wall Street closed lower on Tuesday, pulled down by health care, tech and discretionary stocks.
In Article Trend: Neutral
May 7, 2025 (11:26) / "Zacks Commentary" (by Zacks Equity Research)
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations
Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.
In Article Trend: Neutral
May 7, 2025 (06:01) / "GlobeNewswire" (by Arbutus Biopharma Corporation)
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver ( EASL ) Congress 2025
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B ( cHBV ) patients when combined with VTP-300 and low dose ...
In Article Trend: Neutral
May 6, 2025 (13:54) / "Zacks Commentary" (by Zacks Equity Research)
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.
In Article Trend: Neutral
May 5, 2025 (15:40) / "GlobeNewswire" (by Elis)
May 1, 2025 (17:14) / "Benzinga" (by Vandana Singh)
Moderna Expands Cost-Cutting Program By Up To $1.7 Billion, FDA Approval For Flu/COVID-19 Combo Shot Delayed Into 2026 - Moderna ( NASDAQ:MRNA )
Moderna Q1 EPS loss of $ ( 2.52 ) beat estimates, while revenue hit $108 million, topping forecast despite falling from last year. Spikevax sales reached $84 million in Q1; RSV vaccine mRESVIA saw $2 million in sales after recent international approvals.
In Article Trend: Neutral
May 1, 2025 (15:22) / "Zacks Commentary" (by Zacks Equity Research)
Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts
MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.
In Article Trend: Neutral
May 1, 2025 (11:40) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Reports Q1 Loss, Lags Revenue Estimates
Moderna (MRNA) delivered earnings and revenue surprises of 13.70% and 14.95%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
April 30, 2025 (14:00) / "Benzinga" (by PRNewswire)
ELLIS ISLAND HONORS SOCIETY ANNOUNCES THE 2025 ELLIS ISLAND MEDALS OF HONOR RECIPIENTS
Leaders in business, education, entertainment, public service, philanthropy, media, healthcare, sports, and the defense of the United States to be honored with the prestigious Ellis Island Medals of Honor on May 10th During Gala on Ellis Island
In Article Trend: Bullish
April 29, 2025 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Analysts Estimate Pacira ( PCRX ) to Report a Decline in Earnings: What to Look Out for
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
April 29, 2025 (10:00) / "Benzinga" (by PRNewswire)
BofA Awards Critical Funding for Conservation of Historic Artworks - Bank of America ( NYSE:BAC )
The Art Conservation Project will help restore art from around the world; Sydney Opera House and National Portrait Gallery among recipients CHARLOTTE, N.C., April 29, 2025 /PRNewswire/ -- Sixteen cultural institutions have been named as grant recipients of the 2025 Bank of America Art ...
In Article Trend: Somewhat-Bullish
April 28, 2025 (14:00) / "Benzinga" (by PRNewswire)
ELLIS ISLAND HONORS SOCIETY ANNOUNCES THE 2025 ELLIS ISLAND MEDALS OF HONOR RECIPIENTS
Leaders in business, education, entertainment, public service, philanthropy, media, healthcare, sports, and the defense of the United States to be honored with the prestigious Ellis Island Medals of Honor on May 10th During Gala on Ellis Island
In Article Trend: Bullish
April 28, 2025 (13:16) / "Zacks Commentary" (by Zacks Equity Research)
Countdown to Moderna ( MRNA ) Q1 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
In Article Trend: Somewhat-Bullish
April 28, 2025 (11:48) / "Zacks Commentary" (by Kinjel Shah)
Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.
In Article Trend: Neutral
April 28, 2025 (10:21) / "Motley Fool" (by Eric Volkman)
Down 36%, Is Moderna a Buy on the Dip?
In many ways, the pandemic is becoming a faded memory. With that, a major pandemic star -- biotech Moderna ( NASDAQ: MRNA ) -- also seems to be disappearing from the world's attention. The company's stock is down a headache-inducing 36% year to date, compared to the S&P 500 index's mere 9% ...
In Article Trend: Somewhat-Bullish
April 26, 2025 (13:30) / "Motley Fool" (by Prosper Junior Bakiny)
Market Sell-Off: 2 Stocks Down 17% and 36% This Year to Buy and Hold
What should investors do during a stock-market correction? One great strategy is to go shopping. A bull market will eventually follow the challenging and volatile times we face, and, based on history, this bull run is likely to be longer than the current ordeal.
In Article Trend: Somewhat-Bullish
April 25, 2025 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Moderna (MRNA) settling at $27.19, representing a -0.75% change from its previous close.
In Article Trend: Somewhat-Bullish
April 25, 2025 (19:00) / "Benzinga" (by Benzinga Insights)
Behind the Scenes of Moderna's Latest Options Trends - Moderna ( NASDAQ:MRNA )
Whales with a lot of money to spend have taken a noticeably bullish stance on Moderna. Looking at options history for Moderna MRNA we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 23% ...
In Article Trend: Somewhat-Bullish
April 25, 2025 (15:57) / "Zacks Commentary" (by Zacks Equity Research)
Can Moderna Keep the Beat Streak Alive This Earnings Season?
When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.
In Article Trend: Neutral
April 25, 2025 (14:14) / "Zacks Commentary" (by Zacks Equity Research)
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect
On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.
In Article Trend: Neutral
April 24, 2025 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 20, 2025 (19:10) / "Motley Fool" (by Adria Cimino)
Where Will Moderna Be in 5 Years?
In the early days of the COVID-19 pandemic, Moderna ( NASDAQ: MRNA ) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies, the biotech brought in billions of dollars in annual earnings and saw its stock price jump more than ...
In Article Trend: Neutral
April 17, 2025 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Moderna ( MRNA ) Stock Drops Despite Market Gains: Important Facts to Note
Moderna (MRNA) reachead $24.73 at the closing of the latest trading day, reflecting a -1.85% change compared to its last close.
In Article Trend: Neutral
April 17, 2025 (19:31) / "Benzinga" (by Vandana Singh)
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years - Moderna ( NASDAQ:MRNA ) , GSK ( NYSE:GSK ) , Pfizer ( NYSE:PFE )
CDC estimates 15K-20K RSV hospitalizations yearly among U.S. adults aged 50-59. RSV causes 42K hospitalizations annually in adults aged 50-64, per U.S. study. Feel unsure about the market's next move? Copy trade alerts from Matt Maley-a Wall Street veteran who consistently finds profits in ...
In Article Trend: Somewhat-Bullish
April 16, 2025 (12:00) / "GlobeNewswire" (by Inc.)
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board
Decoy's development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer's extensive scientific knowledge and experience Decoy's development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to ...
In Article Trend: Somewhat-Bullish
April 15, 2025 (10:30) / "GlobeNewswire" (by Inc.)
Serina Therapeutics to Present at the 4th LNP Formulation & Process Development Summit
HUNTSVILLE, AL, April 15, 2025 ( GLOBE NEWSWIRE ) -- Serina Therapeutics, Inc. ( "Serina" ) ( NYSE American: SER ) , a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Randall Moreadith, M.D., Ph.D., Chief Development ...
In Article Trend: Neutral
April 14, 2025 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
In Article Trend: Bullish
